Nycomed retains all rights to Ciclesonide outside the United States and has partnered the product with Teijin Pharmaceuticals in Japan where ALVESCO(R) was launched in June 2007. Nycomed also has rights for the territories outside the United States to certain line extensions and additional products developed by Sepracor under the agreement.
Sepracor develops and markets a range of products in the respiratory field. ALVESCO(R) and Omnaris(TM)complement Sepracor's respiratory portfolio and expand its product pipeline with Ciclesonide line extension programs. These programs include Omnaris(TM) HFA, a hydrofluoroalkane (HFA) metered-dose inhaler Phase II candidate; ALVESCO(R) inhalation solution, a preclinical candidate; and ALVESCO(R) in combination with a long-acting beta-agonist, an early clinical candidate.
"We were looking for a strategic partner both able to commercialise the products and further develop them. With Sepracor we have found that ideal partner," said Hakan Bjorklund, Nycomed's CEO. "This agreement clearly leverages the potential of Ciclesonide that we believe to be one of the most innovative corticosteroids available to patients," he added.
"We are delighted with this agreement, as OMNARIS AQ and ALVESCO HFA
represent two new and exciting products for our 1600 person sales force to
launch in 2008. We are also pleased with the additional development assets
that form part of this ciclesonide franchise," said Adrian Adams, President
and Chief Executive Officer of Sepracor. "The ciclesonide franchise adds
further strength to our growing pipeline and is commercially synergistic
with our XOPENEX(R) and BROVANA(R) franchises. I am particularly pleased
that our core strategy of fully leveraging our existing products,
|SOURCE Nycomed International Management AG|
Copyright©2008 PR Newswire.
All rights reserved